Chiral Partners with TherapiAI to Build an End-to-End AI Digital Twin for Biopharmaceutical Manufacturing

Chiral, an AI scientific computing startup headquartered in Fukuoka, today announced a strategic partnership with TherapiAI, a leading AI company in the biopharmaceutical industry based in Taiwan. Through this collaboration, Chiral becomes TherapiAI's first Japanese partner — marking a significant step in both companies' ambitions to transform biopharma research and manufacturing across Asia.

Chiral's platform enables researchers to run complex computational workflows — including protein structure prediction, molecular docking, and MD simulations — without requiring specialised programming skills. By integrating with TherapiAI's AI Digital Twin infrastructure via API, Chiral's molecular computation capabilities will be embedded directly into an end-to-end pipeline spanning drug design, process development, and manufacturing optimisation.

Solving the R&D-to-Manufacturing Disconnect

The biopharmaceutical industry faces a persistent structural challenge: protein design and process development rely heavily on expert knowledge, while manufacturing data remains fragmented across systems such as MES, LIMS, and QMS. AI models often fail to meet GMP traceability requirements. The result is siloed decision-making that limits both efficiency and innovation.

Chiral has been addressing the upstream part of this problem — eliminating the "glue work" that consumes 40% of researchers' time (Deloitte) by unifying fragmented computational tools into reproducible, shareable Digital Blueprints. The partnership with TherapiAI extends this vision downstream, all the way to manufacturing.

What the Integrated Platform Delivers

The combined platform will cover three critical stages of the biopharma pipeline:

Early-Stage R&D

Chiral's protein 3D structure prediction and manufacturability assessments accelerate antibody and protein drug design while reducing early-stage uncertainty.

Process Development

AI-driven predictive models enable accurate forecasting of yield, purity, and activity — significantly cutting trial-and-error experimentation.

Compliance & Quality

Automated GMP documentation and workflow management ensure full traceability and regulatory compliance across the entire decision chain.

Through this integration, AI evolves from a supporting tool into a living Digital Twin — continuously synchronising virtual models with real-world manufacturing processes.

Executive Perspectives

"At Chiral, we've focused on removing the barriers that slow down computational science — fragmented tools, black-box reproducibility, and weeks lost just setting up environments. Partnering with TherapiAI lets us extend that vision into manufacturing, creating a seamless digital thread from molecule to process. This is exactly the kind of end-to-end infrastructure the Japanese biopharma industry needs."

Wan Qin — Founder and CEO, Chiral

"The competitiveness of biopharma will depend on how deeply AI can be embedded into every stage of drug development. Our collaboration with Chiral allows us to truly connect molecular design with process decision-making — a critical step toward building a truly AI-native infrastructure for the pharmaceutical industry."

Michael Han — Founder and CEO, TherapiAI

Japan First, Then Asia-Pacific

This partnership builds on Chiral's existing relationships with key Japanese industry stakeholders including IMSBIO, JBIC, and Fukuoka Biocommunity alongside a growing base of 100+ global users acquired within the platform's first two months. The two companies will jointly promote AI adoption among Japanese pharmaceutical and biotech companies through co-hosted technical seminars and industry exchange events.

Future expansion plans extend to Singapore and other major biotech hubs across Asia, with Japan serving as the strategic anchor for the region.

Media Contacts

Chiral

• Koji Umeda, COO
• ku@chiral.one
• +81 070-9069-3703
• chiral.one

TherapiAI

• Joan Chang
• +886-928-098-246
• therapiai.bio

About Chiral — Founded in Fukuoka, Japan, Chiral is an AI scientific computing startup enabling advanced computational workflows — including protein structure prediction, molecular docking, and MD simulations — without requiring specialised programming skills. Chiral's Digital Blueprint platform allows researchers to build, reuse, and share end-to-end computational experiments, eliminating the fragmentation and manual overhead that slows down science. Chiral has established partnerships with IMSBIO, JBIC, Fukuoka Biocommunity, and several universities, and has over 100 users globally within two months of launch.

About TherapiAI — Founded in 2018 and headquartered in Taiwan, TherapiAI, Inc. builds AI Digital Twin platforms and AI agents for the biopharmaceutical industry, combining advanced algorithms with real-world domain expertise to enable end-to-end transformation from data integration and process optimisation to intelligent manufacturing decision-making.